# US 2012/0252727 A1 · Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252727 A1
- Document ID: US20120252727A1
- Status: Published application
- Kind: A1
- Application number: 13/062,638
- Filed: 2009-09-04
- Published: 2012-10-04
- Earliest claimed: 2008-09-08
- Assignees: Children's Medical Center Corporation
- Inventors: Wayne I. Lencer; Daniel JF Chinnapen; Randy Mrsny
- Web page: https://patentgrep.com/patent/US20120252727A1

## CPC

- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 31/4164: 1,3-Diazoles
- A61K 38/26: Glucagons
- A61K 39/15: Reoviridae, e.g. calf diarrhea virus
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/544: {Phospholipids}
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2720/12322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2720/12334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).

## Claims

### Claim 1

A delivery vehicle comprising a glycosphingolipid and an agent to be delivered, wherein the glycosphingolipid comprises a ceramide that comprises (a) a short chain fatty acid (C4-C12) or (b) a long chain fatty acid (C14-C28) comprising at least one cis double bond between two carbon atoms and the agent to be delivered is attached to the oligosaccharide of the glycospingolipid.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The delivery vehicle of claim 1, wherein the ganglioside is monosialotetrahexosylganglioside (GM1).

### Claim at position 4

5-7. (canceled)

### Claim 8 (depends on 1)

The delivery vehicle of claim 1, wherein the fatty acid is a C12 fatty acid with no double bonds between carbon atoms or a C16 fatty acid comprising a cis double bond.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The delivery vehicle of claim 1, wherein the agent to be delivered is selected from the group consisting of proteins, peptides, nucleic acids, polysaccharides and carbohydrates, lipids, glycoproteins, and combinations thereof and synthetic organic and inorganic drugs exerting a biological effect when administered to a subject.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The delivery vehicle of claim 1, wherein the agent to be delivered is a therapeutic agent.

### Claim 13

(canceled)

### Claim 14

A glycosphingolipid-therapeutic agent complex comprising a glycosphingolipid attached to a therapeutic agent, wherein the fatty acid of the ceramide comprises (a) 4-12 carbon atoms or (b) 14-28 carbon atoms with at least one cis double bond between two carbon atoms and wherein the therapeutic agent is attached to the oligosaccharide of the glycosphingolipid.

### Claim at position 12

15-16. (canceled)

### Claim 17 (depends on 14)

The ganglioside-therapeutic agent complex of claim 14, wherein the ganglioside is monosialotetrahexosylganglioside (GM1).

### Claim at position 14

18-20. (canceled)

### Claim 21 (depends on 14)

The glycospingolipid-therapeutic agent complex of claim 14, wherein the fatty acid is a C12 fatty acid with no double bonds between carbon atoms or a C16 fatty acid comprising a cis double bond.

### Claim 22

(canceled)

### Claim 23 (depends on 14)

The glycosphingolipid-therapeutic agent complex of claim 14, wherein the agent to be delivered is selected from the group consisting of proteins, peptides, nucleic acids, carbohydrates, lipids, glycoproteins, and combinations thereof and synthetic organic and inorganic drugs exerting a biological effect when administered to a subject.

### Claim at position 18

24-25. (canceled)

### Claim 26

A glycosphingolipid-therapeutic agent complex, wherein the glycosphingolipid comprises a ceramide that comprises (a) a short chain (C4-C12) fatty acid or (b) a long chain (C14-C28) fatty acid comprising a cis double bond and the therapeutic agent is attached to the oligosaccharide of the glycosphingolipid.

### Claim at position 20

27-28. (canceled)

### Claim 29 (depends on 26)

The ganglioside-therapeutic agent complex of claim 26, wherein the ganglioside is monosialotetrahexosylganglioside (GM1).

### Claim at position 22

30-32. (canceled)

### Claim 33 (depends on 26)

The ganglioside-therapeutic agent complex of claim 26, wherein the fatty acid is a C12 fatty acid with no double bonds between carbon atoms or a C16 fatty acid comprising a cis double bond.

### Claim 34

(canceled)

### Claim 35 (depends on 26)

The ganglioside-therapeutic agent complex of claim 26, wherein the agent to be delivered is selected from the group consisting of proteins, peptides, nucleic acids, polysaccharides and carbohydrates, lipids, glycoproteins, and combinations thereof and synthetic organic and inorganic drugs exerting a biological effect when administered to a subject.

### Claim at position 26

36-37. (canceled)

### Claim 38

A ganglioside-therapeutic agent complex comprising monosialotetrahexosylganglioside (GM1) attached to a therapeutic agent, wherein the fatty acid component of the ceramide comprises (a) 4-12 carbon atoms with no double bonds between carbon atoms or (b) 14-28 carbon atoms comprising at least one cis double bond between two carbon atoms and the therapeutic agent is attached to the oligosaccharide of monosialotetrahexosylganglioside (GM1).

### Claim at position 28

39-43. (canceled)

### Claim 44 (depends on 1)

A composition comprising a delivery vehicle of claim 1 and a pharmaceutically acceptable composition.

### Claim 45 (depends on 14)

A composition comprising a ganglioside-therapeutic agent complex of claim 14 and a pharmaceutically acceptable composition.

### Claim at position 31

46-47. (canceled)

### Claim 48 (depends on 1)

A method of delivering an agent into cells/across a mucosal surface, comprising contacting a delivery vehicle of claim 1 with the cells/the mucosal surface, under conditions appropriate for uptake of the delivery vehicle or the agent of interest into the cell or absorption of the delivery vehicle or the agent of interest across the mucosal surface.

### Claim at position 33

49-57. (canceled)

### Claim 58 (depends on 14)

A method of enhancing/increasing the half life of a therapeutic agent in an individual, comprising administering to the individual a ganglioside-therapeutic agent complex of claim 14.

### Claim at position 35

59-60. (canceled)

### Claim 61

A method of treating a disease or condition in an individual in need thereof, comprising administering an effective amount of a ganglioside-therapeutic agent complex to the individual, wherein an effective amount is an amount sufficient to ameliorate/reduce the extent to which the disease or condition occurs in the individual.

### Claim at position 37

62-65. (canceled)

### Claim 66 (depends on 12)

The delivery vehicle of claim 12, wherein the therapeutic agent comprises active GLP1 peptide hormone.

### Claim 67

(canceled)
